尤 斯泰金 單 抗
Stelara (斯特 | |
其他 | CNTO 1275 |
ustekinumab-auub,[1] Wezlana[1] | |
AHFS/Drugs.com | Monograph |
MedlinePlus | a611013 |
| |
给药 | |
ATC碼 | |
药物 | |
15–32 | |
识别 | |
CAS | 815610-63-0 |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
C6482H10004N1712O2016S46 | |
145,648.06 g·mol−1 |
醫療 用途
[编辑]不良 影響
[编辑]懷 孕
[编辑]作用 機轉
[编辑]歷史
[编辑]截至2007
Centocor於2007
社會 與 文化
[编辑]法律 地位
[编辑]FDA於2009
FDA於2016
FDA於2019
生物 相似 藥
[编辑]此藥
參考 文獻
[编辑]- ^ 1.0 1.1 1.2 FDA Approves Interchangeable Biosimilar for Multiple Inflammatory Diseases. U.S. Food and Drug Administration (
新 闻稿). 2023-10-31 [2023-11-13]. (原始 内容 存 档于2023-11-13).本文 含有 此來源 中 屬 於公有 领域的 内容 。 - ^ Ustekinumab (Stelara) Use During Pregnancy. Drugs.com. 2019-11-26. (
原始 内容 存 档于2020-05-22)使用 |archiveurl=
需要 含有 |url=
(帮助).已 忽 略 未知 参 数 |-04-06url=
(帮助); - ^ 3.0 3.1 3.2 3.3 Stelara 45 mg solution for injection (vials) - Summary of Product Characteristics (SmPC). (emc). 2020-02-27 [2020-04-06]. (
原始 内容 存 档于2020-04-06). - ^ 4.0 4.1 4.2 4.3 4.4 4.5 Stelara- ustekinumab injection, solution Stelara- ustekinumab solution. DailyMed. 2020-03-24 [2020-04-06]. (
原始 内容 存 档于J2019-07-02). - ^ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 Stelara EPAR. European Medicines Agency (EMA). 2018-09-17 [2020-04-06]. (
原始 内容 存 档于2020-04-06). - ^ 6.0 6.1 6.2 Ustekinumab. The American Society of Health-System Pharmacists. [2017-01-08]. (
原始 内容 存 档于2017-02-02). - ^ Cingoz O. Ustekinumab. mAbs. 2009, 1 (3): 216–221. PMC 2726595 . PMID 20069753. doi:10.4161/mabs.1.3.8593.
- ^ 8.0 8.1 EC approves expanded use of Stelara for moderately to severely active ulcerative colitis. Healio.com. [2019-09-26]. (
原始 内容 存 档于2019-09-09). - ^ Ustekinumab (Stelara) PBS listed for severe Crohn's disease. NPS Medicinewise. 2017-10-26 [2019-10-04]. (
原始 内容 存 档于2019-04-18). - ^ Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. The Lancet. Neurology. September 2008, 7 (9): 796–804. PMID 18703004. S2CID 20290673. doi:10.1016/S1474-4422(08)70173-X.
- ^ Reddy M, Davis C, Wong J, Marsters P, Pendley C, Prabhakar U. Modulation of CLA, IL-12R, CD40L, and IL-2Ralpha expression and inhibition of IL-12- and IL-23-induced cytokine secretion by CNTO 1275. Cellular Immunology. May 2007, 247 (1): 1–11. PMID 17761156. doi:10.1016/j.cellimm.2007.06.006.
- ^ Toussirot E. The IL23/Th17 pathway as a therapeutic target in chronic inflammatory diseases. Inflammation & Allergy - Drug Targets. April 2012, 11 (2): 159–168. PMID 22280236. doi:10.2174/187152812800392805.
- ^ Important Safety Information. Stelara (ustekinumab). Janssen Biotech. 2019-05-22 [2010-12-31]. (
原始 内容 存 档于2021-03-29). - ^ Weber J, Keam SJ. Ustekinumab. BioDrugs. 2009, 23 (1): 53–61. PMID 19344192. S2CID 265771199. doi:10.2165/00063030-200923010-00006.
- ^ Koutruba N, Emer J, Lebwohl M. Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis. Therapeutics and Clinical Risk Management. April 2010, 6: 123–141. PMC 2857612 . PMID 20421912. doi:10.2147/tcrm.s5599 .
- ^ Bianca Maria Wittig, Bianca Maria. Drug evaluation: CNTO-1275, a mAb against IL-12/IL-23p40 for the potential treatment of inflammatory diseases. Current opinion in investigational drugs. November 2007, 8 (11): 947–54 [2024-01-03]. (
原始 内容 存 档于2024-01-03). - ^ FDA Issues Complete Response Letter to Centocor for Ustekinumab Biologic License Application. Drugs.com (
新 闻稿). Centocor. 2009-09-25 [2020-04-06]. (原始 内容 存 档于2020-04-06). - ^ Medarex to Receive Milestone Payment for Approval of Stelara (Ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis. [2008-12-16]. (
原始 内容 存 档于2013-08-01). - ^ Application to Add Ustekinumab to the World Health Organization’s Essential Medicines List for the treatment of severe psoriasis (PDF). Medicines Working Group of The International League of Dermatological Societies. [2024-01-03]. (
原始 内容 存 档 (PDF)于2024-01-03).In addition, in 2013, the US Food and Drug Administration (FDA) approved the use of ustekinumab for the treatment of psoriatic arthritis
- ^ CENTER FOR DRUG EVALUATION AND RESEARCH Approval Package for: APPLICATION NUMBER: 1252610rigls103 (PDF). CENTER FOR DRUG EVALUATION AND RESEARCH. 2013-09-20 [2024-01-03]. (
原始 内容 存 档 (PDF)于2024-01-03). - ^ drugbank.ca. [2019-10-04]. (
原始 内容 存 档于2020-01-31). - ^ Stelara approved for moderate to severe psoriasis. Sept 2009. 2009-09-26 [2010-07-06]. (
原始 内容 存 档于2015-09-20). - ^ Drug Approval Package: Stelara (Ustekinumab) Injection NDA #125261. U.S. Food and Drug Administration (FDA). 1999-12-24 [2020-04-06]. (
原始 内容 存 档于2020-04-06). - ^ Stelara (ustekinumab) Injection NDA #761044. U.S. Food and Drug Administration (FDA). 2018-01-12 [2020-04-06]. (
原始 内容 存 档于2020-04-06). - ^ 2017-09-12. [2019-10-04]. (
原始 内容 存 档于2021-03-15). - ^ Janssen's Stelara Gets FDA Approval for Ulcerative Colitis. FDA News. [2019-10-31]. (
原始 内容 存 档于2020-01-13). - ^ Stelara: FDA-Approved Drugs. U.S. Food and Drug Administration (FDA). [2020-04-06]. (
原始 内容 存 档于2020-10-20). - ^ 28.0 28.1 28.2 28.3 Uzpruvo: Pending EC decision. European Medicines Agency (EMA). 2023-11-10 [2023-11-13]. (
原始 内容 存 档于2023-11-10).